Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market size was valued at US$ million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. With recovery from influence of COVID-19 and the Russia-Ukraine War, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market.
Key Features:
The report on 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. It may include historical data, market segmentation by Type (e.g., Vials, Pre-filled), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine industry. This include advancements in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine technology, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine new entrants, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine new investment, and other innovations that are shaping the future of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market.
Market Segmentation:
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market?
What factors are driving 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market opportunities vary by end market size?
How does 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
According to our LPI (LP Information) latest study, the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market size was valued at US$ million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. With recovery from influence of COVID-19 and the Russia-Ukraine War, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market.
Key Features:
The report on 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. It may include historical data, market segmentation by Type (e.g., Vials, Pre-filled), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine industry. This include advancements in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine technology, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine new entrants, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine new investment, and other innovations that are shaping the future of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market.
Market Segmentation:
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Vials
- Pre-filled
- Hospital
- Clinic
- CDC
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Kangtai
- Walvax Biotechnology
What is the 10-year outlook for the global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market?
What factors are driving 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine market opportunities vary by end market size?
How does 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Country/Region, 2018, 2022 & 2029
2.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Segment by Type
2.2.1 Vials
2.2.2 Pre-filled
2.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
2.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Type (2018-2023)
2.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 CDC
2.5 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
2.5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Application (2018-2023)
3 GLOBAL 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE BY COMPANY
3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Breakdown Data by Company
3.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Company (2018-2023)
3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Company (2018-2023)
3.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Company
3.4 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Location Distribution
3.4.2 Players 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth
4.4 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth
4.5 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth
4.6 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth
5 AMERICAS
5.1 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country
5.1.1 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023)
5.1.2 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023)
5.2 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
5.3 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Region
6.1.1 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Region (2018-2023)
6.1.2 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Region (2018-2023)
6.2 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
6.3 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Country
7.1.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023)
7.1.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023)
7.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
7.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Country
8.1.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
8.3 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
10.3 Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
10.4 Industry Chain Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Distributors
11.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Customer
12 WORLD FORECAST REVIEW FOR 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE BY GEOGRAPHIC REGION
12.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size Forecast by Region
12.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Forecast by Region (2024-2029)
12.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Forecast by Type
12.7 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
13.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Kangtai
13.2.1 Kangtai Company Information
13.2.2 Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
13.2.3 Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Kangtai Main Business Overview
13.2.5 Kangtai Latest Developments
13.3 Walvax Biotechnology
13.3.1 Walvax Biotechnology Company Information
13.3.2 Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
13.3.3 Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Walvax Biotechnology Main Business Overview
13.3.5 Walvax Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Country/Region, 2018, 2022 & 2029
2.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Segment by Type
2.2.1 Vials
2.2.2 Pre-filled
2.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
2.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Type (2018-2023)
2.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 CDC
2.5 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
2.5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Application (2018-2023)
3 GLOBAL 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE BY COMPANY
3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Breakdown Data by Company
3.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Company (2018-2023)
3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Company (2018-2023)
3.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Company
3.4 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Location Distribution
3.4.2 Players 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth
4.4 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth
4.5 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth
4.6 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth
5 AMERICAS
5.1 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country
5.1.1 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023)
5.1.2 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023)
5.2 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
5.3 Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Region
6.1.1 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Region (2018-2023)
6.1.2 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Region (2018-2023)
6.2 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
6.3 APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Country
7.1.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023)
7.1.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023)
7.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
7.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine by Country
8.1.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type
8.3 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
10.3 Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
10.4 Industry Chain Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Distributors
11.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Customer
12 WORLD FORECAST REVIEW FOR 13-VALENT PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE BY GEOGRAPHIC REGION
12.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market Size Forecast by Region
12.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Forecast by Region (2024-2029)
12.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Forecast by Type
12.7 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
13.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Kangtai
13.2.1 Kangtai Company Information
13.2.2 Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
13.2.3 Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Kangtai Main Business Overview
13.2.5 Kangtai Latest Developments
13.3 Walvax Biotechnology
13.3.1 Walvax Biotechnology Company Information
13.3.2 Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
13.3.3 Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Walvax Biotechnology Main Business Overview
13.3.5 Walvax Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Vials
Table 4. Major Players of Pre-filled
Table 5. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Table 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Type (2018-2023) & ($ million)
Table 8. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Type (2018-2023)
Table 9. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 11. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Table 12. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Application (2018-2023)
Table 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Application (2018-2023)
Table 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Company (2018-2023) & (K Units)
Table 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Company (2018-2023)
Table 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Company (2018-2023)
Table 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Producing Area Distribution and Sales Area
Table 21. Players 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Products Offered
Table 22. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share Geographic Region (2018-2023)
Table 27. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country/Region (2018-2023)
Table 31. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 34. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 35. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 37. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 38. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 39. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Region (2018-2023) & (K Units)
Table 40. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Region (2018-2023)
Table 41. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Region (2018-2023)
Table 43. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 44. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 45. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 46. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 47. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 49. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 50. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Table 58. Key Market Challenges & Risks of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Table 59. Key Industry Trends of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Table 60. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Distributors List
Table 63. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Customer List
Table 64. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Pfizer Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
Table 80. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Kangtai Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
Table 85. Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Kangtai Main Business
Table 87. Kangtai Latest Developments
Table 88. Walvax Biotechnology Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
Table 90. Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Walvax Biotechnology Main Business
Table 92. Walvax Biotechnology Latest Developments
Table 1. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Vials
Table 4. Major Players of Pre-filled
Table 5. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Table 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Type (2018-2023) & ($ million)
Table 8. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Type (2018-2023)
Table 9. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 11. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Table 12. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Application (2018-2023)
Table 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Application (2018-2023)
Table 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Company (2018-2023) & (K Units)
Table 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Company (2018-2023)
Table 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Company (2018-2023)
Table 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Producing Area Distribution and Sales Area
Table 21. Players 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Products Offered
Table 22. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share Geographic Region (2018-2023)
Table 27. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country/Region (2018-2023)
Table 31. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 34. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 35. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 37. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 38. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 39. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Region (2018-2023) & (K Units)
Table 40. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Region (2018-2023)
Table 41. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Region (2018-2023)
Table 43. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 44. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 45. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 46. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 47. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 49. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 50. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Table 58. Key Market Challenges & Risks of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Table 59. Key Industry Trends of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Table 60. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Distributors List
Table 63. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Customer List
Table 64. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Pfizer Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
Table 80. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Kangtai Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
Table 85. Kangtai 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Kangtai Main Business
Table 87. Kangtai Latest Developments
Table 88. Walvax Biotechnology Basic Information, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Product Portfolios and Specifications
Table 90. Walvax Biotechnology 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Walvax Biotechnology Main Business
Table 92. Walvax Biotechnology Latest Developments
LIST OF FIGURES
Figure 1. Picture of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Figure 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Vials
Figure 10. Product Picture of Pre-filled
Figure 11. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type in 2022
Figure 12. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Type (2018-2023)
Figure 13. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Consumed in Hospital
Figure 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market: Hospital (2018-2023) & (K Units)
Figure 15. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Consumed in Clinic
Figure 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market: Clinic (2018-2023) & (K Units)
Figure 17. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Consumed in CDC
Figure 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market: CDC (2018-2023) & (K Units)
Figure 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2022)
Figure 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Application in 2022
Figure 21. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market by Company in 2022 (K Units)
Figure 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Company in 2022
Figure 23. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Company in 2022
Figure 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Geographic Region in 2022
Figure 27. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 28. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 29. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 30. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 32. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 35. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country in 2022
Figure 36. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 37. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 38. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 39. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Region in 2022
Figure 44. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Regions in 2022
Figure 45. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 46. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 47. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country in 2022
Figure 55. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 56. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 57. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 58. Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 59. France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country in 2022
Figure 64. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 67. Egypt 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine in 2022
Figure 73. Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Figure 74. Industry Chain Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Figure 75. Channels of Distribution
Figure 76. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Forecast by Region (2024-2029)
Figure 77. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Figure 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Vials
Figure 10. Product Picture of Pre-filled
Figure 11. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type in 2022
Figure 12. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Type (2018-2023)
Figure 13. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Consumed in Hospital
Figure 14. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market: Hospital (2018-2023) & (K Units)
Figure 15. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Consumed in Clinic
Figure 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market: Clinic (2018-2023) & (K Units)
Figure 17. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Consumed in CDC
Figure 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Market: CDC (2018-2023) & (K Units)
Figure 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2022)
Figure 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Application in 2022
Figure 21. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market by Company in 2022 (K Units)
Figure 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Company in 2022
Figure 23. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Company in 2022
Figure 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Geographic Region in 2022
Figure 27. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 28. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 29. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 30. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 32. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue 2018-2023 ($ Millions)
Figure 35. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country in 2022
Figure 36. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 37. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 38. Americas 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 39. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Region in 2022
Figure 44. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Regions in 2022
Figure 45. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 46. APAC 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 47. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country in 2022
Figure 55. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 56. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 57. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 58. Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 59. France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Country in 2022
Figure 64. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share by Application (2018-2023)
Figure 67. Egypt 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine in 2022
Figure 73. Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Figure 74. Industry Chain Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Figure 75. Channels of Distribution
Figure 76. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Forecast by Region (2024-2029)
Figure 77. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine Revenue Market Share Forecast by Application (2024-2029)
